Skip to content
You can now search across every topic, entity and event.What's new
Pandemics and Biosecurity
21JUL

WHO defers vaccine-sharing pact to 2027

3 min read
09:12UTC

WHA79 deferred the Pandemic Agreement's vaccine-sharing annex to 2027, leaving the treaty's equity core inoperative during an emergency that has no licensed product to share.

ScienceDeveloping
Key takeaway

The treaty's vaccine-sharing core stays unfinished until 2027, just as an outbreak with no licensed product needs it.

The 79th World Health Assembly (WHA79) deferred adoption of the Pandemic Agreement's Pathogen Access and Benefit-Sharing (PABS) annex to WHA80 in May 2027, or to an earlier special session if a text is ready 1. The next negotiating round, the seventh Intergovernmental Working Group session (IGWG7), is set for 6 to 17 July 2026 2. PABS is the part of the treaty meant to guarantee that countries which share virus samples receive fair access to the vaccines made from them. Tedros Adhanom Ghebreyesus said real progress had been made, and member states cited a need for more time 3.

This is the second slip in a month: negotiators had already agreed to extend the PABS talks at the resumed sixth IGWG session on 1 May . The annex has stalled because high-income states resist binding sharing obligations they fear will constrain their own manufacturers, the same fault line that has dogged every benefit-sharing negotiation since the 2007 dispute over Indonesian H5N1 samples.

The timing gives the deferral its edge. The treaty's vaccine-sharing core stays inoperative at the exact moment a novel-species emergency with no licensed countermeasure would have tested it. If a Bundibugyo vaccine reaches trials this year, there is still no binding legal route to push doses to the low-income countries carrying the outbreak; allocation stays at the discretion of manufacturers and the buyers WHO can pay first. The world adopted the treaty in 2024 and, two years on, still cannot do the one thing its equity advocates designed it to do.

Deep Analysis

In plain English

When a new dangerous virus emerges, countries need to share samples of it quickly so that scientists around the world can study it and start making vaccines. The problem is that in past pandemics, like H1N1 in 2009, the countries that shared their virus samples did not get any of the vaccines that were made from those samples. Rich countries bought them all first. PABS (Pathogen Access and Benefit-Sharing) is meant to be the rule that fixes this: countries share samples and in return get guaranteed access to vaccines produced from them. The 79th World Health Assembly, which met in Geneva in May 2026, pushed the decision on PABS to a 2027 meeting because member states cannot agree on how the rules would work in practice. During the current Bundibugyo Ebola outbreak, there is no licensed vaccine for this species at all; the PABS negotiations apply to future outbreaks where a sharing-and-access mechanism could make the difference between equitable and inequitable vaccine distribution.

First Reported In

Update #4 · Ebola triples, response misfires

Konrad-Adenauer-Stiftung Geneva Multilateral Dialogue· 24 May 2026
Read original
Different Perspectives
UK Government
UK Government
The Biological Security Strategy implementation report published 14 July commits the UK to deciding within twelve months whether to make DNA-synthesis screening mandatory, backed by GBP 1.83bn for biosecurity centres. It is a preemptive move on a threat that has not yet produced a UK incident.
Cambodia's Ministry of Health
Cambodia's Ministry of Health
Cambodia confirmed a nine-month-old girl in Phnom Penh as its fourth 2026 H5N1 case on 11 July, the country supplying four of the world's seven new human cases since February. The ministry's confirmed-case cadence is running well ahead of a US surveillance system that has recorded nothing new since March.
Knowledge Ecology International
Knowledge Ecology International
KEI published proposed annex text on the day IGWG7 opened that would attach benefit-sharing duties to a product's market registration, regardless of whether the manufacturer used shared samples or only downloaded sequence data. It is the Africa Group's fallback position if the sample-based bargain fails to bind.
European Union
European Union
The EU and other industrialised states backed a hybrid model built on centralised infrastructure with more flexible access terms, the opposite design choice from the Africa Group's. Brussels wants conditions handled contractually once samples reach shared facilities, not attached to national custody of the material itself.
Africa Group / Algeria
Africa Group / Algeria
Algeria, speaking for the Africa Group at IGWG7, backed distributed national and regional laboratories under binding access conditions, arguing that supplying states must keep legal control of samples rather than surrender them into shared infrastructure.
Uganda's Ministry of Health
Uganda's Ministry of Health
Uganda discharged its last confirmed patient on 16 July and opened a 42-day countdown to declaring its own outbreak over, closing at 20 cases and 2 deaths with no new case since 21 June. This is a closing chapter running alongside DR Congo's still-worsening one, contingent on a border DRC can no longer see across.